CONFORMA ACQUIRES COMPOUND FROM SUMITOMO

Conforma Therapeutics Corporation and Sumitomo Pharmaceuticals (Osaka, Japan) has announced that they have reached a licensing agreement for Amrubicin HCl (Amrubicin), a third-generation, totally synthetic anthracycline anti-cancer drug. Conforma has obtained exclusive rights, including sublicensing rights, to develop and market Amrubicin in North America and Europe. Amrubicin is currently approved and marketed in Japan for small-cell and non-small-cell lung cancer (under the brand name Calsed). Sumitomo will manufacture the product for worldwide distribution. Financial terms of the agreement were not disclosed.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=252456&categoryid=10)